REFERENCES

1. WORLD HEALTH ORGANIZATION (1996). World malaria situation in 1993. Weekly Epidemiological Record, 71:17-24.

2. WORLD HEALTH ORGANIZATION (1994). Antimalarial drug policies: data requirements, treatment of uncomplicated malaria and the management of malaria in pregnancy. Unpublished document. WHO/MAL/94.1070.

3. HARINASUTA, T. and BUNNAG, D. (1988). The clinical features of malaria. In Malaria: Principles and Practice of Malariology. Vol. 1, 709-734, Editors W.H. Wemsdorfer and I.A. McGregor. Churchill Livingstone, Edinburgh.

4. GILLES, H.M. (1988). The differential diagnosis of malaria. In Malaria: Principles and Practice of Malariology. Vol. 1, 769-779, Editors W.H. Wernsdorfer and I.A. McGregor. Churchill Livingstone, Edinburgh.

5. WORLD HEALTH ORGANIZATION (1990). Practical chemotherapy of malaria. Report of a WHO Scientific Group. Technical Report Series No 805, Geneva.

6. WORLD HEALTH ORGANIZATION (1986). Expert Committee on Malaria. Eighteenth Report. WHO Technical Report Series No 735, Geneva.

7. WORLD HEALTH ORGANIZATION (1992). Expert Committee on Malaria. Nineteenth Report. WHO unpublished document, WHO/CTD/92.1.

8. ARMSTRONG-SCHELLENBERG, J.R.M., SMITH, T., ALONSO, P.L. et al. (1994). What is clinical malaria? Finding case definitions for field research in highly endemic areas. Parasitology Today, 10: 439-442.

9. REDD, S.C., BLOLAND, P.B., KAZEMBE, P.N. et al. (1992). Usefulness of clinical case-definitions in guiding therapy for African children with malaria or pneumonia. Lancet, 340: 1140-1143.

10. PETERS, D.H. and GRAY, R.H. (1992). When is fever malaria? Lancet, 339: 690.

11. SCHAPIRA, A. (1994). A standard protocol for assessing the proportion of children presenting with febrile disease who suffer from malarial disease. WHO unpublished document, WHO/MAL/94.1069.

12. OLIVAR, M., DEVELOUX, M., ABARI, A.C. (1991). Presumptive diagnosis of malaria results in a significant risk of mistreatment of children in urban Sahel. Transactions of the Royal Society of Tropical Medicine, 85: 729-730.

13. WORLD HEALTH ORGANIZATION (1992). A Training Guide for District Health Workers on Malaria Control in Tropical Africa. Brazzaville, WHO Regional Office for Africa.

14. BYASS, P., CAMPBELL, H., O’DEMPSEY, T.J. et al. (1991). Coincidence of malaria parasitaemia and abnormal chest X-ray findings in young Gambian children. Journal of Tropical Medicine and Hygiene, 94: 22-23.

15. REDD, S.C., BLOLAND, P.B., KAZEMBE. P.N. et al. (1992). Usefulness of clinical case-definitions in guiding therapy for African children with malaria or pneumonia. Lancet, 340: 1140-1143.

16. O’DEMPSEY, T.J.D., McARDLE, T.F, LAURENCE, B.E. et al. (1993). Overlap in the clinical features of pneumonia and malaria in African children. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87: 662-665.

17. WORLD HEALTH ORGANIZATION (1991). Acute respiratory infections in children: case management in small hospitals in developing countries. WHO unpublished document, WHO/ARI/91.20.

18. WORLD HEALTH ORGANIZATION (1995). Management of childhood illness. WHO unpublished documents, WHO/CDR/95.14A-L.

19. WORLD HEALTH ORGANIZATION (1993). Implementation of the Global Malaria Control Strategy. Report of a WHO Study Group. Technical Report Series No. 839, Geneva.

20. PAYNE, D. (1988). Use and limitations of light microscopy for diagnosing malaria at the primary health care level. Bulletin of the World Health Organization, 66: 621-626.

21. DOWLING, M.A.C. and SHUTE, G.T. (1966). A comparative study of thick and thin blood films in the diagnosis of scanty malaria parasitaemia. Bulletin of the World Health Organization, 34: 249-267.

22. WORLD HEALTH ORGANIZATION (1985). Bench aids for the diagnosis of malaria. Plates 1-8, Geneva.

23. BELJAEV, A.E., BROHULT, J.A., SHARMA, G.K. et al (1995). Studies on the detection of malaria at primary health centres. Part 1. Reliability of parasitological diagnosis by decentralized laboratories. Indian Journal of Malariology, 22: 85-103.

24. WARDLOW, S.C. and LEVINE, R.A. (1983). Quantitative buffy coat analysis: a new laboratory tool functioning as a screening complete blood cell count. Journal of American Medical Association, 249: 617-620.

25. DIETZE, R., PERKINS, M., BOULOS, M., et al. (1995). The diagnosis of Plasmodium falciparum infection using a new antigen detection system. American Journal of Tropical Medicine and Hygiene, 52: 45-49.

26. UGUEN, C., RABODONIRINA, M., DE PINA, J-J. et al. (1995). Parasight R-F rapid manual diagnostic test of P. falciparum. Bulletin of the World Health Organization, 73: 643-649.

27. BEADLE, C., LONG, G.W., WEISS, W.R. et al. (1994). Diagnosis of malaria detection of Plasmodium falciparum HRP-2 antigen with rapid dipstick antigen capture assay. Lancet, 343: 564-568.

28. SHIFF, C.J., PREMJI, Z. and MINJAS, J.N. (1993). The rapid manual ParaSight F test. A new diagnostic tool for Plasmodium falciparum infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87: 646-648.

29. PREMJI, Z., MINJAS, J.N. and SHIFF, C.J. (1994). Laboratory diagnosis of malaria by village health workers using the rapid manual ParaSight F test. Transaction of the Royal Society of Tropical Medicine and Hygiene, 88: 418

30. WORLD HEALTH ORGANIZATION (1996). A rapid dipstick antigen capture assay for the diagnosis of falciparum malaria. Bulletin of the World Health Organization, 74: 47-54.

31. MAKLER, M.T. and HINDRICHS, D.J. (1993). Measurement of the lactic dehydrogenase activity of Plasmodium falciparum as an assessment of parasitaemia. American Journal of Tropical Medicine and Hygiene, 48: 205-210.

32. KNOBLOCH, J. and HENK, M. (1995). Screening for malaria by determination of parasite-specific lactic dehydrogenase. Transactions of the Royal Society of Tropical Medicine, 89: 269-270.

33. THARAVANIJ, S. (1990). New developments in malaria diagnostic techniques. Southeast Asian Journal of Tropical Medicine and Public Health, 21: 3-16.

34. WORLD HEALTH ORGANIZATION (1988). Malaria diagnosis: memorandum from a WHO meeting. Bulletin of the World Health Organization, 66: 575-594.

35. INSTITUTE OF MEDICINE (1991). Malaria: Obstacles and Opportunities. Stanley C. Oaks, Jr., Violaine S Mitchell, Greg W. Pearson and Charles C.J. Carpenter (editors), National Academy Press, Washington D.C., 309pp.

36. WATERS, A.P. and McCUTCHAN, T.F. (1989). Rapid sensitive diagnosis of malaria based on ribosomal RNA. Lancet, 1: 1343-1346

37. ARAI, M., MIZUKOSHI, C., KUBOCHI, F. et al. (1994). Detection of Plasmodium falciparum in human blood by a nested polymerase chain reaction. American Journal of Tropical Medicine Hygiene, 51: 617-626.

38. OLIVEIRA, D.A., HOLLOWAY, B.P., DURIGON, E.L., et al. (1995). Polymerase chain reaction and a liquid-phase, nonisotopic hybridization for species-specific and sensitive detection of malaria infection. American Journal of Tropical Medicine and Hygiene, 52: 139-144.

39. OLIVEIRA, D.A., SHI, Y.P., OLOO, A.J. et al. (1996). Field evaluation of a polymerase chain reaction-based nonisotopic liquid hybridization assay for malaria diagnosis. Journal of Infectious Diseases, 173: 1284-1287.

40. SNOUNOU, G., VIRIYAKOSOL, S., ZHU, X.P. et al.(1993). High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reactions. Molecular and Biochemical Parasitology, 61: 315-320.

41. LI, J., WIRTZ, R.A., McCONKEY, G.A., et al. (1995). Plasmodium: Genus-conserved primers for species identification and quantitation. Experimental Parasitology, 81: 182-190.

42. HULIER, E., PETOV, R.P., SNOUNOU, G. et al. (1996). A method for the quantitative assessment of malaria parasite development in organs of the mammalian host. Molecular and Biochemical Parasitology, 77: 127-135.

43. CENTERS FOR DISEASE CONTROL (1988). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health care and public-safety workers. Morbidity and Mortality Weekly Report, 38: No. S-6.

44. WORLD HEALTH ORGANIZATION (1991). Risk of transmission of AIDS and other blood-related diseases during routine malaria activities. Bulletin of the World Health Organization, 69: 242-243.

45. WORLD HEALTH ORGANIZATION (1991). Biosafety guidelines for diagnostic and research laboratories working with HIV. WHO AIDS Series No 9, pp 28.

46. MARSH, K., FORSTER, D, WARUIRU, C. et al. (1995). Indicators of life-threatening malaria in African Children. New England Journal of Medicine, 332: 1399-1404.

47. WORLD HEALTH ORGANIZATION (1993). The management and prevention of diarrhoea: practical guidelines. Third edition, WHO, Geneva, pp 50.

48. WORLD HEALTH ORGANIZATION (1995). The treatment of diarrhoea: a manual for physicians and other senior health workers. WHO unpublished document, WHO/CDR/95.3.

49. WORLD HEALTH ORGANIZATION (1990). Severe and complicated malaria. D.A. Warrell, M.E. Molyneux and P.F. Beales (editors). Transactions of the Royal Society of Tropical Medicine and Hygiene, 84: Supplement 2, pp65.

50. BRABIN, B.J. (1992). The role of malaria in nutritional anemias. In: Nutritional anemias. S.J. Fomon and S. Ziotkin, (editors). Raven Press, New York and, pp65-80.

51. WEATHERALL, D.J. and ABDALLA S. (1982). The anaemia of Plasmodium falciparum malaria. British Medical Bulletin, 38: 147-151.

52. BLOLAND, P.B., LACKRITZ, E.M., KAZEMBE, P.N. et al., (1993). Beyond chloroquine: Implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. Journal of Infectious Diseases, 167: 932-937.

53. LACKRITZ, E.M., CAMPBELL, C.C., RUEBUSH, T.K. et al. (1993). Effect of blood transfusion on survival among children in a Kenyan hospital. Lancet, 340: 524-528.

54. HOLZER, B.R., EGGER, M., TEUSCHER, T. et al. (1993). Childhood anaemia in Africa: to transfuse or not transfuse? Acta Tropica, 55: 47-51.

55. JACKSON, R.T. and LATHAM, M.C. (1982). Anaemia of pregnancy in Liberia, West Africa: a therapeutic trial. American Journal of Clinical Nutrition, 35: 710-714.

56. FLEMING, A.F., GHATOURA, G.B.S., HARRISON, K.A. et al. (1986). The prevention of anemia in pregnancy in primigravidae in the guinea savanna of Nigeria. Annals of Tropical Medicine and Parasitology, 80: 211-233.

57. THAITHONG, S., SUEBSAENG, L., ROONEY, W. et al. (1988). Evidence of increased chloroquine sensitivity in Thai isolates of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82: 37-38.

58. RIECKMANN, K.H., DAVIS, D.R. and HUTTON, D.C. (1989). Plasmodium vivax resistance to chloroquine? Lancet, ii: 1183-1184.

59. WHITBY, M., WOOD, G., VEENENDAAL, J.R. et al. (1989). Chloroquine-resistant Plasmodium vivax. Lancet, ii: 1395.

60. COLLIGNON, P. (1991). Chloroquine resistance in Plasmodium vivax. Journal of Infectious Diseases, 164: 222-223.

61. SCHWARTZ, I.K., LACKRITZ, E.M. and PATCHEN, L.C. (1991). Chloroquine-resistant Plasmodium vivax from Indonesia. New England Journal of Medicine, 324: 927.

62. BAIRD, J.K., BASRI, H., PURNOMO, et al. (1991). Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 44: 547-552.

63. SCHUURKAMP, G.J. (1992). The epidemiology of malaria and filariasis in the Ok Tedi region of Western Province, Papua New Guinea. Port Moresby, Papua New Guinea: University of New Guinea, pp 341.

64. SCHUURKAMP, G.J., SPICER, P.E., KEREU, R.K. et al. (1992). Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 86: 121-122.

65. MYAT-PHONE- KYAW, MYINT-OO, MYINT-LWIN et al. (1993). Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Transactions of the Royal Society of Tropical Medicine and Hygiene, 87: 687.

66. MURPHY, G.S., BASRI, H., PURNOMO et al. (1993). Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet, 341: 96-100.

67. SEXTON, J.D., DELORON, P., BUGILIMFURA, L. et al. (1988). Parasitologic and clinical efficacy of 25 and 50 mg/kg of chloroquine for treatment of Plasmodium falciparum malaria in children. American Journal of Tropical Medicine and Hygiene, 38: 237-243.

68. WORLD HEALTH ORGANIZATION (1984). Advances in malaria chemotherapy. Report of a WHO Scientific Group, Technical Report Series No 711, Geneva.

69. OLLIARO, P.L., NEVILL, C., LE BRAS, J. et al. (1996). Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet, 348: 1196-1201.

70. HATTON, C.S.R., PETO, T.E, BUNCH, C. et al. (1986). Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet, i: 411-414.

71. NEFTEL, K.A., WOODLY, W., SCHMIDT, R. et al. (1986). Amodiaquine-induced agranulocytosis and liver damage. British Medical Journal, 292: 721-723.

72. STEFFEN, R. and HEUSSER, R. (1986). Fiabilité et effets secondaires de la prophylaxie du paludisme. Medicine et hygiene, 44: 2125-2127.

73. FREYENMUTH, T. (1987). Agranulocytose und Leberschädigung durch Amodiaquine. University of Zurich (PhD Thesis).

74. WINSTANLEY, P.A., SIMOOYA, O., KOFI-EKUE, J.M. et al. (1990). The disposition of amodiaquine in Zambians and Nigerians with malaria. British Journal of Clinical Pharmacology, 29: 695-701

75. PHILLIPS-HOWARD, P. and WEST, L.J. (1990). Serious adverse reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. Journal of the Royal Society of Medicine, 83: 82-85.

76. WINSTANLEY, P.A., COLEMAN, J.W., MAGGS, J.L. et al. (1990). The toxicity of amodiaquine and its principle metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units. British Journal of Clinical Pharmacology, 29: 479-485.

77. PARK, B.K. and KITTERINGHAM, N.R. (1990). Drug-protein conjugation and its immunological consequences. Drug Metabolism Reviews, 22: 87-144.

78. JAEGER, A., SAUDER, P., KOPFERSCHMITT, J. et al. (1987). Clinical features and management of poisoning due to antimalarial drugs. Medical Toxicology, 2: 242-273.

79. LEGE-OGUNTOYE, L., ADAGU, S.I., WERBLINSKA, B. et al. (1990) Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine combination in semi-immune children in Zaria, northern Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 84: 505 -506.

80. SCHAPIRA, A. (1990). The resistance of falciparum malaria in Africa to 4-aminoquinolines and antifolates. Scandanavian Journal of Infectious Diseases, 75 (Suppl): 1-64.

81. MSUYA,F. and CURTIS, C.F. (1991). Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic for malaria. 4. Effect on incidence of malaria infection. Acta Tropica, 49: 165-171.

82. TRIGG, J.K., MBWANA, M., HILLS, E. et al. (1997). Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in North East Tanzania and a test of chlorproguanil/dapsone. Tropical Medicine and International Health, (in press).

83. DOBERSTYN, E.B., TEERAKIARTKAMJORN, C., ANDRE, R.G. et al. (1979). The treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Transactions of the Royal Society of Tropical Medicine and Hygiene, 73: 15-17.

84. WATKINS, W.M, SIXSMITH, D.G., CHULAY, J.D. et al. (1985). Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Molecular and Biochemical Parasitology, 14: 55-63.

85. STEKETEE, R.W., WIRIMA, J.J., SLUTSKER, L. et al. (1994). Malaria prevention in pregnancy: the effects of treatment and chemoprophylaxis on placental infection, low birth weight, and fetal, infant and child survival. CDC/ARTS (99-4048), United States Department of Health and Human Services.

86. WERNSDORFER, W.H. and TRIGG, P.I. (1988). Recent progress of malaria research: chemotherapy. In Malaria: Principles and Practice of Malariology. Vol. 2, 1569-1674, Editors W.H. Wernsdorfer and I.A. McGregor; Churchill Livingstone, Edinburgh.

87. DOST, F.H. and GLADTKE, E. (1969). Pharmakokinetik des 2-sulfanilamido-3-methoxy-pyrazins beim Kind (Elimination, enterale Absorption, Verteilung und Dosierung). Artzeimittelforschung, 19: 1304-1307.

88. COOPMAN, S.A., JOHNSON, R.A., PLATT, R., et al. (1993). Cutaneous disease and drug reactions in HIV infection. The New England Journal of Medicine, 328: 1670-1674.

89. MILLER, K.D., LOBEL. H. O., SATRIALE, R.F., et al. (1986). Severe cutaneous reactions among American travellers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. American Journal of Tropical Medicine and Hygiene, 35: 451-458.

90. WORLD HEALTH ORGANIZATION (1992). The overlap in the clinical presentation and treatment of malaria and pneumonia in children. WHO unpublished document, WHO/ARI/92.23.

91. REYNOLDS, J.E.F. (Editor) (1993). Martindale: the extra pharmacopoeia. The Pharmacceutical Press, London, pp2263.

92. BJORKMAN, A. and PHILLIPS-HOWARD, P.A. (1991). Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bulletin of the World Health Organization, 69: 297-304.

93. DUPONT, H.L. ERICSSON, C.D., JOHNSON, P.C. et al. (1986). Antimicrobial agents in the prevention of travelers diarrhea. Reviews in Infectious Diseases, 8: Suppl. 2, S167-S171.

94. LOOAREESUWAN, S, VIRAVAN, C., WEBSTER, H.K. et al. (1996). Clinical studies of atovaquone, alone or in combination with other drugs, for treatment of acute uncomplicated malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 54: 62-66.

95. CANFIELD, C.J., PUDNEY, M. and GUTTERIDGE, W.E. (1995). Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Experimental Parasitology, 80: 373-381.

96. MBERU, E.K., WANSOR, T., SATO, H. et al. (1995). Japanese poor metabolizers of proguanil do not have an increased risk of malaria chemoprophylaxis breakthrough. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89: 658-659.

97. PETERSON, D.S., MILHOUS, W. and WELLEMS, T.E. (1990). Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proceedings of the National Academy of Sciences, USA, 87: 3018-3022.

98. PLOWE, C.V., DJIMDE, A., BOUARE, M. et al. (1995). Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. American Journal of Tropical Medicine and Hygiene, 52: 565-658.

99. JAMALUDIN, A., MOHAMAD, M., NAVARATNAM, V. et al. (1990). Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100mg proguanil hydrochloride. Tropical Medicine and Parasitology, 41: 268-272.

100. THAITHONG, S., BEALE, G.H. and CHUTMONGKONKUL, M. (1988) Variability in drug susceptibility amongst clones and isolates of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82: 33-36.

101. SWARTZ, D.E., STURCHLER, D. and KOUP, J. (1986). Mefloquine absorption half-life from the commercial tablet Ro 21-5998/603. Solubility of the hydrochloride considered as a possible limiting factor to influence the rate and extent of absorption. Roche Research Report No 8-153’133.

102. CREVOISIER, C. TILLEMENT, J.P., BARRE, J. et al. (1992). Food increases the bioavailability of mefloquine. Proceedings of the XIIIth International Congress of Tropical Medicine and Malaria, Jomtien, Pattaya, Thailand, Abstract ThP7-1,p268.

103. ter KUILE, F.O., NOSTEN, P., LUXEMBURGER, C. et. al. (1995). Mefloquine treatment of acute falciparum malaria: a prospective study of non serious adverse effects in 3673 patients. Bulletin of the World Health Organization, 73: 631-642.

104. EDSTEIN M.D., VEENENDAAL, J.R. and HYSLOP, R..(1988). Excretion of mefloquine in human breast milk. Chemotherapy, 34: 165-169.

105. KARBWANG, J. and WHITE, N.J. (1990). Clinical pharmacokinetics of mefloquine. Clinical Pharmacokinetics, 19: 264-279.

106. MARTIN, C., GIMINEZ, P., BANGCHANG, K.N. et al. (1994). Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers. European Journal of Clinical Pharmacology, 47: 85-87.

107. STEFFEN, R., FUCHS, E., SCHILDKNECHT, J., et al. (1993). Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet, 341: 1299-1303.

108. PHILLIPS-HOWARD, P.A. and ter KUILE, F.O. (1995). CNS adverse events associated with antimalarial agents: fact or fiction? Drug Safety, 12: 370-383.

109. WEINKE, T., TRAUTMANN, M., HELD, T. et al. (1991). Neuropsychiatric side effects after the use of mefloquine. American Society of Tropical Medicine and Hygiene, 45: 86-91.

110. SOWUNMI, A., SALAKO, L.A., ODUOLA. A.M.J. et al. (1993). Neuropsychiatric side effects of mefloquine in Africans. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87: 462-463.

111. WORLD HEALTH ORGANIZATION (1991). Review of central nervous system adverse events related to the antimalarial drug mefloquine (1985-1990). WHO unpublished document, WHO/MAL/91.1063.

112. BEM, J.L., KERR, L. and STURCHLER, D. (1992). Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. Journal of Tropical Medicine and Hygiene, 95: 167-79.

113. PHILLIPS, M.A. and KASS, R.B. (1996). User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. Journal of Travel Medicine, 3: 40-45.

114. VUURMAN, E., MUNTJEWERFF, N., UITERWIJK, M. et al. (1997). Effects of mefloquine, alone and with alcohol on psychomotor and driving performance. European Journal of Clinical Pharmacology: (in press).

115. ter KUILE, F.O., LUXEMBURGER, C., NOSTEN, F. et al. (1994). Serious neuro-psychiatric adverse events following mefloquine treatment: evidence for a dose relationship? In: Mefloquine, halofantrine, and artesunate in the treatment of uncomplicated falciparum malaria. PhD thesis, Amsterdam, p 173-182.

116. BOUDREAU, E., SCHUSTER, B., SANCHEZ, J. et al. (1993). Tolerability of prophylactic Lariam regimens. Tropical Medicine and Parasitology, 44: 257-65.

117. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES (1990). International reporting of adverse reactions, CIOMS, Geneva, pp66.

118. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES (1992). International reporting of perodic - safety update summaries, CIOMS, Geneva, pp 36.

119. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES (1995). Guidelines for preparing core clinical - safety information on drugs, CIOMS, Geneva, pp 69.

120. LOBEL, H.O., MIANI, M., ENG, T. et al. (1993). Long-term malaria prophylaxis with weekly mefloquine. Lancet, 341: 848-851.

121. BARRETT, P.J., EMMINS, P.D., CLARKE, P.D. et al. (1996). Comparison of adverse reactions associated with the use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. British Medical Journal, 313: 525-528.

122. EKUE, J.M.K., ULRICH, A.-M., RWABWOGO, J. et al. (1983). A double blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bulletin of the World Health Organization, 61: 713-18.

123. NOSTEN, F., ter KUILE, F.O., LUXEMBURGER, C. et al. (1993). Cardiac effects of antimalarial treatment with halofantrine. Lancet, 341: 1054-56.

124. KARBWANG, J., NA-BANGCHANG, K., THANAVIBUL, A. et al. (1994). Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria. Bulletin of the World Health Organization, 72: 233-38.

125. DAVIS, T.M.E. (1995). Safety of mefloquine in healthy volunteers: a double blind, placebo-controlled trial. In: Mefloquine (Lariam) in special situations: New data. p 4, paper presented at the Fourth International Conference on Travel Medicine. Acapuico, Mexico, April 23-27.

126. WORLD HEALTH ORGANIZATION (1996). International travel and health: vaccination requirements and health advice. WHO, Geneva, pp104.

127. DANIS, M., NOZAIS, J.P, PARIS, L. et al. (1993). Fièvre bilieuse haemoglobinurique après prise de mefloquine. 3 observations. Presse Médicale, 22: 80.

128. MARTIN, G.J., MALONE, J.L. and ROSS, E.V. (1993). Exfoliative dermatitis during malarial prophylaxis with mefloquine. Clinical and Infectious Diseases, 16: 341-2.

129. VAN DEN ENDEN, E., VAN COMPEL, A., COLEBUNDERS, R. et al. (1991). Mefloquine-induced Stevens-Johnson syndrome. Lancet, 337: 683.

130. SHLIM, D.R. (1991). Severe facial rash associated with mefloquine. Journal of the American Medical Association, 266: 2560.

131. SCERRI, L. and PACE, J.L. (1993). Mefloquine-associated cutaneous vasculitis. International Journal of Dermatology, 32: 517-518.

132. PATCHEN, L.C., CAMPBELL, C.C. and WILLIAMS, S.B. (1989). Neurological reactions after a therapeutic dose of mefloquine. New England Journal of Medicine, 321: 1415-1416.

133. SCHLAGENHAUF, P., LOBEL, H.O., STEFFEN, R., et al. (1997). Tolerability of mefloquine in Swissair trainee pilots. American Journal of Tropical Medicine and Hygiene, (in press).

134. HESSEN-SODERMAN, A.C., BERGENIUS, J., BERGGREN-PALME, I. et al. (1995). Hearing, postural control and vestibular functions during mefloquine prophylaxis. In: Programs and Abstracts of the Fourth International Conference on Travel Medicine. Acapulco, Mexico, April 23-27, p 87.

135. KARBWANG, J., NA BANGCHANG, K., BACK, D.J. et al., (1992). Effect of tetracycline on mefloquine pharmacokinetics in Thai males. European Journal of Clinical Pharmacology, 43: 567-569.

136. KARBWANG, J., NA BANGCHANG, K., BACK, D.J. et al. (1991). Effect of ampicillin on mefloquine pharmacokinetics in Thai males. European Journal of Clinical Pharmacology, 40: 631 -633.

137. SUEBSAENG, L, WERNSDORFER, W.H. and ROONEY, W. (1986). Sensitivity to quinine and mefloquine of Plasmodium falciparum in Thailand. Bulletin of the World Health Organization, 64: 759-765.

138. WANWIMOLRUK, S., CHALCROFT, S., COVILLE, P.F. et al. (1991). Pharmacokinetics of quinine in young and elderly subjects. Transactions of the Royal Society of Tropical Medicine and Hygiene, 85: 714-717.

139. WINSTANLEY, P.A., NEWTON, C., WATKINS, W. et al. (1993). Towards optimal regimens of parenteral quinine for young African children with cerebral malaria; the importance of unbound quinine concentration. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87: 201 -206.

140. SUPANARANOND, W., DAVIS, T.M., PUKRITTAYAKAMEE, S. et al. (1993). Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs. European Journal of Clinical Pharmacology, 44: 325-329.

141. BUNNAG, D., HARINASUTA, T, LOOARESUWAN, S. et al. (1989). A combination of quinine, quinidine and cinchonine (LA 40221) in the treatment of chloroquine-resistant falciparum malaria in Thailand: two double blind trials. Transactions of the Royal Society of Tropical Medicine and Hygiene, 83: 66.

142. BASCO, L.K. and LEBRAS, J. (1992). In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 47: 521-527.

143. BASCO, L. K. and LEBRAS, J. (1994). In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artemisinin derivatives. Annals of Tropical Medicine and Parasitology, 88: 137-144.

144. PETERS, W., ROBINSON, B.L. and ELLIS, D.L. (1987). The chemotherapy of rodent malaria. XLII: halofantrine and halofantrine resistance. Annals of Tropical Medicine and Parasitology, 81: 65-67.

145. NATEGHPOUR, M., WARD, S. and HOWELLS, R.E. (1993). Development of halofantrine resistance and determination of cross-resistance patterns in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 37: 2337-2343.

146. HORTON, R.J. (1994). Halofantrine treatment of acute falciparum malaria in infants and young children. Mitteilungen der Österreichischen Gesellschaft fur Tropenmedizin und Parasitologie, 16: 87-92.

147. MILTON, K.A, EDWARDS, G., WARD, S.A. et al. (1989). Pharmacokinetics of halofantrine in man: effects of food and dose size. British Journal of Clinical Pharmacology, 28: 71 -77.

148. SHANKS, G.D., WATT, G., EDSTEIN, M.D. et al. (1992). Halofantrine given with food for falciparum malaria. Transactions of the Royal Society of Tropical Medcine and Hygiene, 86: 233-234.

149. MONLUN, E., LE METAYER, P., SZWANDT, S. et al. (1995). Cardiac complications of halofantrine: a prospective study of 20 patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89: 430-433.

150. SCHUSTER, B.G. and CANFIELD, C. J. (1989). Preclinical studies with halofantrine. In Halofantrine in the treatment of multidrug resistant malaria, Editors, D.C. Warhurst and C.J. Schofield, Parasitology Today, Suppl. pp 65-79.

151. KARBWANG, J. and BANGCHANG, K.N. (1994). Clinical pharmacokinetics of halofantrine. Clinical Pharmacokinetics, 27: 104-119.

152. CASTOT, A., RAPOPORT, P. and LECOZ, P. (1993). Prolonged QT interval with halofantrine. Lancet, 341: 1541.

153. MONLUN, E., PILLET, O., COCHARD, J.C.F. et al. (1993). Prolonged QT interval with halofantrine. Lancet, 341: 1541-1542.

154. NOSTEN, F., ter KUILE, F.O, LUXEMBURGER, C. et al. (1993). Cardiac effects of antimalarial treatment with halofantrine. Lancet, 341: 1054-1056.

155. MOJON, M., WALLON, M., GRAVEY, A. et al. (1994). Intravascular haemolysis following halofantrine intake. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88: 91.

156. WORLD HEALTH ORGANIZATION (1994). The role of artemisinin and its derivatives in the current treatment of malaria (1994-1995). WHO unpublished document, WHO/MAL/94.1067.

157. PRICE, R.N, NOSTEN, F, LUXEMBURGER, C. et al. (1996). Effects of artemisimn derivatives on malaria transmissibility. Lancet, 347: 1654-1658.

158. BUNNAG, D., VIRAVAN, C., LOOARESUWAN, S. et al. (1991). Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 22: 534-538.

159. BUNNAG, D., VIRAVAN, C., LOOAREESUWAN, S. et al. (1991). Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 22: 539-543.

160. BUNNAG, D., KARBWANG, J. and HARINASUTA, T. (1992). Artemether in the treatment of multiple drug resistant falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 23: 762-767.

161. BUNNAG, D., KARBWANG, J., CHITAMAS, S. et al. (1993). Intramuscular artemether in female patients with uncomplicated falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 24: 49-52.

162. LOOAREESUWAN, S., VIRAVAN, C., VANIJANONTA, S. et al. (1992). Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet, 339: 821-824.

163. KARBWANG, J., NA BANGCHANG, K., THANAVIBOL, A. et al. (1992). Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria. Lancet, 340: 1245-1248.

164. LOOAREESUWAN, S., VIRAVAN, C., VANIJANONTA, S. et al. (1996). Comparative clinical trial of artesunate followed by mefloquine in the treatment of acute uncomplicated falciparum malaria: 2 and 3 day regimens. American Journal of Tropical Medicine and Hygiene, 54: 210-213.

165. BUNNAG, D., KANDA, T., KA RBWANG, J. et al. (1995) Artemether-mefloquine combination in multidrug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89: 213-215.

166. KARBWANG, J., NA BANGCHANG, K., THANAVIBOL, A. et al. (1995). A comparative clinical trial of two different regimens of artemether plus mefloquine in multiresistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89: 296-298.

167. LOOAREESUWAN, S., VANIJANONTA, S., VIRAVAN, C. et al. (1994). Randomized trial of mefloquine alone and artesunate followed by mefloquine for the treatment of acute uncomplicated falciparum malaria. Annals of Tropical Medicine and Parasitology, 88: 131 -136.

168. NOSTEN, F. (1991). Artemisinin: large community studies. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88: Suppl. 1,45-49.

169. PRICE, R.N., NOSTEN, F. LUXEMBURGER, C. et al. (1995). Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89: 523-527.

170. LI, G.Q., GUO, X.B., FU, L.C. et al. (1994). Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88: Suppl. 1, 5-6.

171. QINGHAOSU ANTIMALARIAL COORDINATING COMMITTEE (1979). Antimalarial studies on qinghaosu. Chinese Medical Journal, 92: 811-816.

172. WANG, T.Y. (1989). Therapeutic effectiveness and toxic side-effects of artemisinin and artemether for the treatment of malaria patients in pregnancy. Journal of Traditional Chinese Medicine, 9: 28-30.

173. NA BANGCHANG, K., KARBWANG, J., THOMAS, C.G. et al. (1994). Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute uncomplicated falciparum malaria. British Journal of Clinical Pharmacology, 37: 249-253.

174. BREWER, T.G., GRATE, S.J., PEGGINS, J.O. et al. (1994). Fatal neurotoxicity of arteether and artemether. American Journal of Tropical Medicine and Hygiene, 51: 251-259.

175. PETRAS, J.M., BREWER, T.G. and PEGGINS, J.O. (1993). Brain injury induced in Rattus rattus by the antimalarial drug arteether (AE): a neuroanatomical and neuropathological analysis. Anatomical Record, 237 (suppl. 1): 95.

176. GENOVESE, R.F., PETRAS, J.M. and BREWER, T.G. (1995). Arteether neurotoxicity in the absence of deficits in behavioural performance in rats. Annals of Tropical Medicine and Parasitology, 89: 447-449.

177. HEIN, T.T. and WHITE, N.J. (1993). Qinghaosu. Lancet, 341: 603-608.

178. OLLIARO, P.L. and TRIGG P.I. (1995). Status of antimalarial drugs under development. Bulletin of the World Health Organization, 73: 565-571.

179. SCHIMDT, L.H., FRADKIN, R., VAUGHAN, D. et al. (1977). Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. American Journal of Tropical Medicine and Hygiene, 26: 1118-1128.

180. BAIRD, J.K., FRYAUFF, D.J., BASRI, H. et al. (1995). Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. American Journal of Tropical Medicine and Hygiene, 52: 479-484.

181. FRYAUFF, D.J., BAIRD, J.K., BASRI, H. et al. (1995). Randomized placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet, 346:1190-1193.

182. WEISS, W.R, OLOO, A.J., JOHNSON, A. et al. (1995). Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline and chloroquine plus proguanil. Journal of Infectious Diseases, 171:1569-1575.

183. SHANKS, G.D., BARNETT, A., EDSTEIN, M.D. et al. (1995). Effectiveness of doxycycline combined with primaquine for malaria prophlaxis. Medical Journal of Australia, 162: 306-307.

184. WERNSDORFER, W.H. and TRIGG, P.I. (1984). Primaquine: Pharmacokinetics, metabolism, toxicity and activity. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Geneva, pp164.

185. SHANKS, G.D., ROESSLER, P., EDSTEIN, M.D. et al. (1995). Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nation Missions in Somalia and Cambodia. Militiary Medicine, 160: 443-445.

186. LOOAREESUWAN, S., VIRAVAN, C, VANIJANONTA, S. et al. (1994). Randomized trial of mefloquine-doxycycline and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria. American Journal of Tropical Medicine and Hygiene, 50: 784-789.